Edition:
United States

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

2.03USD
23 Apr 2018
Change (% chg)

$-0.05 (-2.41%)
Prev Close
$2.08
Open
$2.05
Day's High
$2.10
Day's Low
$2.03
Volume
58,980
Avg. Vol
96,765
52-wk High
$2.85
52-wk Low
$1.17

Chart for

About

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its... (more)

Overall

Beta: 2.28
Market Cap(Mil.): $127.08
Shares Outstanding(Mil.): 62.39
Dividend: --
Yield (%): --

Financials

  AFMD.OQ Industry Sector
P/E (TTM): -- 185.04 32.78
EPS (TTM): -0.84 -- --
ROI: -77.46 -0.74 13.21
ROE: -85.95 -2.80 15.01

BRIEF-Affimed Announces Proposed Public Offering Of Common Stock

* AFFIMED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

Feb 12 2018

BRIEF-Affimed Reports New Data For AFM13 From Two Separate Clinical Trials

* AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS

Feb 01 2018

BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash

* Affimed presents data from Phase 1B combination study of AFM13 with Pembrolizumab at Ash

Dec 11 2017

BRIEF-Affimed reports Q3 loss per share EUR 0.18

* Q3 earnings per share view EUR -0.17 -- Thomson Reuters I/B/E/S

Nov 07 2017

BRIEF-Affimed announces Q3 financial results and corporate update conference call

* Affimed announces third quarter 2017 financial results and corporate update conference call Source text for Eikon: Further company coverage:

Oct 30 2017

Earnings vs. Estimates